Tesamorelin Results: Timeline, Before & After & What to Expect (2026)
From Peptidepedia, the trusted peptide wiki.
Medical Advisory Board
Results Timeline
Weeks 1-4:
Significant visible changes typically do not occur during initial periods
GH and IGF-1 levels elevate internally
Some individuals report improved sleep quality, increased energy, and enhanced exercise recovery
Weeks 4-8:
Subtle body composition improvements become noticeable, including mild abdominal bloating reduction
Improved skin quality
Laboratory testing typically shows elevated IGF-1 levels
Weeks 8-16:
More pronounced visceral fat reductions become apparent
Clinical trials demonstrated statistically significant visceral adipose tissue reduction by weeks 12-16
Users often report improved muscle definition, particularly in abdominal regions
Weeks 16-26:
Continued progressive improvement in body composition
The pivotal Phase III trials showed approximately 15-18% reduction in visceral adipose tissue (measured by CT scan) at 26 weeks
Lipid profile improvements, including reduced triglycerides, typically become measurable
Beyond 26 Weeks:
Extended treatment continues maintaining or further improving results
The 52-week extension studies demonstrated sustained benefits with continued use
Frequently Asked Questions
Most users begin noticing subtle improvements in body composition between weeks 8-12, with more significant visceral fat reduction becoming apparent by weeks 16-26. Clinical trials demonstrated statistically significant results at the 26-week mark.
Clinical trials have evaluated tesamorelin use for up to 52 weeks with maintained efficacy and acceptable safety profiles. However, long-term data beyond this period remains limited, and discontinuation typically results in gradual return of visceral fat accumulation.
This content is for educational and informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making any health-related decisions.
References
Falutz J, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. New England Journal of Medicine. 2007;357(23):2359-2370.
Falutz J, et al. Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat. Journal of Clinical Endocrinology & Metabolism. 2010;95(9):4291-4304.
Stanley TL, et al. Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation. JAMA. 2014;312(4):380-389.
Makimura H, et al. Effects of tesamorelin on cardiometabolic risk factors in HIV-infected patients. Journal of Clinical Endocrinology & Metabolism. 2011;96(9):2831-2838.
Fourman LT, et al. Tesamorelin treatment for liver fat and histology in HIV-associated NAFLD. Journal of Clinical Investigation. 2019;129(11):4608-4615.
Baker LD, et al. Effects of growth hormone-releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults. Archives of Neurology. 2012;69(11):1420-1429.
Sevigny JJ, et al. Growth hormone secretagogue MK-677: no clinical effect on AD progression in a randomized trial. Neurology. 2008;71(21):1702-1708.
Dhillon S. Tesamorelin: A Review of its Use in the Management of HIV-Associated Lipodystrophy. Drugs. 2011;71(8):1071-1091.
FDA Prescribing Information for Egrifta SV (tesamorelin).
World Anti-Doping Agency 2024 Prohibited List.
Spooner LM, et al. Tesamorelin: A Growth Hormone-Releasing Factor Analogue for HIV-Associated Lipodystrophy. Annals of Pharmacotherapy. 2012;46(2):240-247.
Stanley TL, et al. Effects of tesamorelin on inflammatory markers in HIV patients with excess abdominal fat. AIDS. 2011;25(10):1281-1288.